China Jo-Jo Drugstores Files 2024 Annual Report

TL;DR

Jo-Jo Drugstores filed its 2024 20-F, check financials for the year ending March 31.

AI Summary

China Jo-Jo Drugstores, Inc. filed its annual report on Form 20-F for the fiscal year ended March 31, 2024. The company, previously known as China Jo-Jo Drugstores Holdings, Inc., is incorporated in E9 and operates in the retail drug store sector. Its principal executive offices are located in Hangzhou, China.

Why It Matters

This filing provides investors with the company's audited financial performance and operational details for the past fiscal year, offering insights into its business health and future prospects.

Risk Assessment

Risk Level: medium — As a foreign private issuer filing a 20-F, the company operates under different regulatory frameworks and may present unique risks to investors compared to domestic US companies.

Key Numbers

• 0331 — Fiscal Year End (Indicates the end of the reporting period for financial statements.)
• 001-40724 — SEC File Number (Unique identifier for the company's filings with the SEC.)

Key Players & Entities

• China Jo-Jo Drugstores, Inc. (company) — Registrant
• March 31, 2024 (date) — Fiscal year end
• China Jo-Jo Drugstores Holdings, Inc. (company) — Former company name
• 001-40724 (dollar_amount) — SEC file number
• Hangzhou (company) — City of business address

FAQ

Key Financial Figures

• $0.24 — registered Ordinary shares, par value $0.24 per share CJJD Nasdaq Capital Market
• $ — er to the legal currency of China; "US$," "U.S. dollars," "$," and "dollars" re
• $17.5 million — n capital raising. We raised capital of $17.5 million in our IPO in April 2010. In addition,
• $39.863 million — we raised capital for a total amount of $39.863 million from 2015 to 2024 through various finan
• $27.5 million — t to Jiuxin Management is approximately $27.5 million and $8.7 million, respectively. Jiuxin
• $8.7 m — ment is approximately $27.5 million and $8.7 million, respectively. Jiuxin Management
• $18.58 million — has distributed a loan of approximately $18.58 million to Jiuzhou Pharmacy, a loan of approxim
• $1.03 million — uzhou Pharmacy, a loan of approximately $1.03 million to Jiuzhou Service, a loan of approxima
• $0.20 million — iuzhou Service, a loan of approximately $0.20 million to Jiuzhou Clinic, a loan of approximat
• $1.01 million — Jiuzhou Clinic, a loan of approximately $1.01 million to Linjia Medical, a loan of approximat
• $0.14 — Linjia Medical, a loan of approximately $0.14 to Shouantang Bio. Additionally, Jiux
• $60 million — zhou Pharmacy ranges from approximately $60 million to $80 million. All the sales and pur
• $80 million — anges from approximately $60 million to $80 million. All the sales and purchases between

Filing Documents

• ea0209917-20f_chinajojo.htm (20-F) — 2139KB
• ea020991701ex12-1_chinajojo.htm (EX-12.1) — 9KB
• ea020991701ex12-2_chinajojo.htm (EX-12.2) — 13KB
• ea020991701ex13-1_chinajojo.htm (EX-13.1) — 7KB
• ea020991701ex15-1_chinajojo.htm (EX-15.1) — 2KB
• ea020991701ex97-1_chinajojo.htm (EX-97.1) — 31KB
• image_001.jpg (GRAPHIC) — 115KB
• image_002.jpg (GRAPHIC) — 45KB
• fin_001.jpg (GRAPHIC) — 2KB
• ex15-1_001.jpg (GRAPHIC) — 5KB
• 0001013762-24-002657.txt ( ) — 9317KB
• cjjd-20240331.xsd (EX-101.SCH) — 90KB
• cjjd-20240331_cal.xml (EX-101.CAL) — 62KB
• cjjd-20240331_def.xml (EX-101.DEF) — 348KB
• cjjd-20240331_lab.xml (EX-101.LAB) — 605KB
• cjjd-20240331_pre.xml (EX-101.PRE) — 346KB
• ea0209917-20f_chinajojo_htm.xml (XML) — 1098KB

Business

Business Overview 38 C. Organizational Structure 43 D. Property, Plants and Equipment 47 Item 4A. Unresolved Staff Comments 47 Item 5. Operating and Financial Review and Prospects 47 A. Operating Results 47 B. Liquidity and Capital Resources 57 C. Research and Development, Patents and Licenses, etc. 57 D. Trend Information 57 E. Critical Accounting Estimates 58 Item 6. Directors, Senior Management and Employees 58 A. Directors and Senior Management 58 B. Compensation 60 C. Board Practices 64 D. Employees 65 E. Share 66 F. Disclosure of a registrant's action to recover erroneously awarded compensation 66 Item 7. Major Shareholders and Related Party Transactions 67 A. Major Shareholders 67 B. Related Party Transactions 67 C. Interests of Experts and Counsel 67 Item 8. Financial Information 68 A. Consolidated 68 B. Significant Changes 68 Item 9. The Offer and Listing 68 A. Offer and Listing Details 68 B. Plan of Distribution 68 C. Markets 68 D. Selling shareholders 68 E.

Dilution

Dilution 68 F. Expenses of the issue 68 Item 10. Additional Information 69 A. Share Capital 69 B. Memorandum and Articles of Association 69 C. Material Contracts 74 D. Exchange Controls 74 E. Taxation 75 F. Dividends and Paying Agents 76 G. by Experts 76 H. Documents on Display 76 I. Subsidiary Information 76 J. Annual Report to Security Holders 76 i Item 11. Quantitative and Qualitative Disclosures about Market Risk 76 Item 12. Description of Securities Other than Equity Securities 78 A. Debt Securities 78 B. Warrants and Rights 78 C. Other Securities 78 D. American Depositary Shares 78 Part II Item 13. Defaults, Dividend Arrearages and Delinquencies 79 Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 79 Item 15. Controls and Procedures 79 Item 16. [Reserved] 80 Item 16A. Audit Committee Financial Expert 80 Item 16B. Code of Ethics 80 Item 16C. Principal Accountant Fees and Services 81 Item 16D. Exemptions from the Listing Standards for Audit Committees 81 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 82 Item 16F. Change in Registrant's Certifying Accountant 82 Item 16G. Corporate Governance 82 Item 16H. Mine Safety Disclosure 82 Item 16I Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 82 Item 16J Insider trading policies 83 Item 16K Cybersecurity 83 Part III Item 17. Financial 84 Item 18. Financial 84 Item 19. Exhibits 84 Index to Consolidated Financial Statements F-1 ii PART I ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS. Not applicable. ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE. Not applicable. ITEM 3. KEY INFORMATION. China Jo-Jo Drugstores, Inc. ("CJJD", the "Company", "we", "our", or "us") is not a Chinese operating company but

View Full Filing

View this 20-F filing on SEC EDGAR